Table 2.
anti-BCMA CAR T-Cell Studies: outcomes.
| Car t Cell Construct | Idecabtagene Vicleucel (bb2121) |
Ciltacabtagene Autoleucel (JNJ-4528) |
Orvacabtagene Autoleucel (JCAR-H125) |
Idecabtagene Vicleucel (ide-cel, bb2121) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Author (Year) | Munshi (2020) | Berdeja (2019) Alsina (2020) |
Berdeja (2020) Madduri (2020) |
Mailankody (2020) | Lin (2020) | ||||||
| Study Name | KarMMa | CRB-402 | CARTITUDE-1 | EVOLVE | CRB-401 | ||||||
| Reference | [24] | [25,26] | [27,28] | [29,30] | [31] | ||||||
| Response Rate | |||||||||||
| ORR | 50% | 69% | 82% | 83% | 43% | 73% | 97% | 95% | 89% | 92% | 76(%) |
| CR | 25% | 29% | 39% | 18% | 67% | 37% | 42% | 29% | 39(%) | ||
| Median DoR | NR | 9.9 | 11.3 | 11.9 | NR | NR | NR | NR | 10.3(%) | ||
| Median PFS | 2.8 | 5.8 | 12.1 | NR | NR | NR | NR | 9.3 | NR | NR | 8.8 (%) |
| Evaluable for MRD | 4 | 70 | 54 | 7 | 6 | 4 | 57 | 11 | 11 | 3 | 37 |
| MRD- | 50% | 31% | 48% | 100% | 83.3% | 100% | 93% | 72.7% | 90.9% | 100% | 81% |
| CRS Event | |||||||||||
| All | 50% | 76% | 96% | 67% | 94.8% | 89% | 76(%) | ||||
| Median Time to First Onset | 7 (2–12) | 2 (1–12) | 1 (1–10) | 3 (1–20) | 7 (1–12) | 2 (1–4) | Nk | ||||
| Grade 3–4 | 0 | 4% | 6% | 2% | 4% | 3% | 6(%) | ||||
| Grade 5 | 0 | 1% | 0 | 2% | 1% | 0 | 0 | ||||
| Neurotoxicities | |||||||||||
| All | 0 | 17% | 20% | 22% | 20.6% | 13% | 44% | ||||
| Median Time to First Onset | NA | 3 (1–10) | 2 (1–5) | 7 (3–24) | 8 (3–12) | 4 (1–6) | Nk | ||||
| Grade 3–4 | 0 | 7% | 12% | 4% | 10.3% | 3% | 3% | ||||
| Grade 5 | 0 | 0 | 0 | 2% | 0 | 0 | 0 | ||||
B-cell maturation antigen (BCMA); median time to first onset expressed in days (range); median age expressed in years (range); median follow up and progression-free survival (PFS) expressed in months; overall response rate (ORR); complete remission (CR): median duration of response (DoR) expressed in months; not known (Nk).